Tirzepatide dosage: what the schedule looks like and why it works that way

You've just been prescribed 2.5 mg and you're wondering when it will actually do anything

That feeling (a mix of cautious hope and mild impatience) is something our prescribers hear about often. The 2.5 mg starting pen can feel anticlimactic, and that's partly the point. Its job isn't to drive significant weight loss; it's to let your digestive system meet tirzepatide gradually, minimising the nausea and discomfort that can come from moving too fast. Think of it as the first rung on a ladder that only gets effective once you're a few rungs up.

After four weeks on 2.5 mg, the standard progression is to 5 mg. Clinical trial evidence (published in the SURMOUNT-1 paper in the New England Journal of Medicine) showed that participants at 15 mg achieved an average body-weight reduction of around 20–21% over 72 weeks. That outcome was built on this same slow step-up. Rushing the schedule doesn't accelerate results; it tends to worsen side effects and sometimes pushes people to stop treatment early. For a fuller look at what the 5 mg dose involves, including what to expect in weeks five to eight, there's a dedicated page worth reading before your next review.

Every dose increase at nume is subject to a fresh clinical review. A named prescriber checks your reported response (not software, not a form filed away) before any step up is confirmed. That's how the schedule is meant to work.

How tirzepatide dosage in ml translates to what you actually inject

A common question, especially for people who've used other injectable medicines before: what does the dose look like in the pen? Mounjaro is supplied as a pre-filled KwikPen; each pen contains four doses delivered once weekly. You don't measure millilitres yourself. The pen is pre-set and pre-dosed, you dial to your prescribed strength, inject subcutaneously into your abdomen, thigh or upper arm, rotate sites, and the device handles the volume.

The SmPC (Summary of Product Characteristics) published on the electronic Medicines Compendium contains the precise volume and concentration information for each strength if you want the pharmacological detail. For practical purposes, the dose you track is in milligrams, not millilitres, the pen takes care of the rest.

Storage matters here too. Mounjaro pens are kept refrigerated at 2–8°C, though there is a limited room-temperature window for travel and day-to-day convenience. The exact duration of that window is specified in the Patient Information Leaflet; always check there rather than relying on memory or online sources, because it varies by strength and storage history.

Moving through the Mounjaro tirzepatide dosage steps: 7.5 mg to 15 mg

Once past 5 mg, the four-weekly step pattern continues: 7.5 mg, then 10 mg, then 12.5 mg, with 15 mg as the licensed maximum. For context on what the 10 mg stage involves (including what evidence says about weight loss at that point in the schedule) that page covers the specifics, and if you want to plan further ahead, our page on reaching and managing the 10 mg tirzepatide dosage goes into additional detail on that step in the schedule. The 15 mg dose is where the SURMOUNT-1 trial recorded its headline results, and NICE's appraisal of tirzepatide (TA1026) is based substantially on that data.

Not everyone will reach 15 mg, and that's fine. Some people respond well at a lower maintenance dose with fewer side effects. The prescriber's role is to find the highest dose you tolerate well, not to hit a ceiling for its own sake. NICE guidance notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed, which is why regular clinical reassessment matters throughout, not just at the start.

The maximum tirzepatide dose and what happens if you reach it are covered in more detail separately, including what the evidence says about outcomes at 15 mg compared with lower maintenance doses.

What determines your personal tirzepatide dosage, and how a consultation fits in

The licensed schedule is the same for everyone at the start. What diverges is how individuals move through it. Factors a prescriber weighs include how well the current dose is tolerated, whether weight loss is progressing appropriately, any changes in health status since the last review, and whether side effects are transient or persistent. The NICE appraisal of tirzepatide (TA1026) sets out the clinical framework within which responsible prescribing operates.

On the practical side, it's worth understanding that the cost of treatment often tracks the dose, higher strengths carry higher list prices. That context, including how UK pricing has shifted since the Eli Lilly price adjustment in September 2025, is covered on our Mounjaro price increase page if you want the background before deciding on a path forward.

There's no shortcut through the dosage schedule, and there shouldn't be. The slow titration is part of what makes tirzepatide manageable for most people over the long run. If you'd like a prescriber to assess where you are in the schedule and whether your current dose is right for you, speaking to our team is the natural next step. Speak to our prescribers through a free consultation and get a same-day clinical review.